Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
Public ClinicalTrials.gov record NCT02728752. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM Study")
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM study")
Study identification
- NCT ID
- NCT02728752
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 95 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 27, 2017 (Actual)
- Primary completion
- Nov 5, 2019 (Actual)
- Completion
- Nov 5, 2019 (Actual)
- Last update posted
- Dec 23, 2021
2017 – 2019
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Octapharma Research Site | Huntington Beach | California | 92647 | — |
| Octapharma Research Site | Los Angeles | California | 90095 | — |
| University of California -Irvine | Orange | California | 92868 | — |
| Octapharma Research Site | Orlando | Florida | 32819 | — |
| NeuroMedical Research Center | Panama City | Florida | 32405 | — |
| Octapharma Research Site | Plantation | Florida | 33324 | — |
| University of South Florida | Tampa | Florida | 33612 | — |
| Octapharma Research Site | Kansas City | Kansas | 66160 | — |
| Octapharma Research Site | Ann Arbor | Michigan | 48109 | — |
| Octapharma Research Site | Rochester | Minnesota | 55905 | — |
| Octapharma Research Site | Great Neck | New York | 11021 | — |
| Octapharma Research Site | Portland | Oregon | 97239 | — |
| Octapharma Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Stones River Dermatology | Murfreesboro | Tennessee | 37130 | — |
| Austin Neuromuscular Center | Austin | Texas | 78756 | — |
| Octapharma Research Site | Houston | Texas | 77034 | — |
| Arthritis & Osteoporosis Clinic | Waco | Texas | 76710 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02728752, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 23, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02728752 live on ClinicalTrials.gov.